Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform

Zhimin Shao, Director of the Breast Cancer Center at FUSCC

“Patients with breast cancer can respond very differently to the same treatment, and we still lack reliable tools to predict those differences.”

Zhimin Shao, Director of the Breast Cancer Center at FUSCC

“We hope this study will identify biological characteristics of tumors before treatment that will allow us to predict outcomes.”

Zhimin Shao, Director of the Breast Cancer Center at FUSCC

“Such discoveries could someday also guide personalized treatment decisions and create new opportunities to improve therapeutic efficacy and patient prognosis.”

Tong Zhou, CEO of SPDx

“By combining FUSCC's clinical expertise with the cellular-resolution view of tumors provided by Xenium, we hope to uncover biomarkers that conventional methods may overlook and ultimately support more precise treatment decisions for patients with breast cancer.”

Roman Yelensky, Vice President, Clinical Applications at 10x Genomics

“Biology is incredibly complex, and many of today's diagnostic approaches capture only a limited view of the cellular interactions and spatial context that may influence treatment response.”

Roman Yelensky, Vice President, Clinical Applications at 10x Genomics

“Single cell and spatial technologies have the potential to enable a new generation of diagnostics informed by deeper insights into disease biology.”

Roman Yelensky, Vice President, Clinical Applications at 10x Genomics

“FUSCC and SPDx are pursuing exactly the kind of ambitious research needed to make that future possible.”

Roman Yelensky, Vice President, Clinical Applications at 10x Genomics

“Their work can move us closer to a world where clinicians have greater clarity about which treatments are most likely to work, transforming cancer care.”